Axsome Logo.png
Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial of AXS-12 in Narcolepsy
September 16, 2021 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Logo.png
Axsome Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
August 09, 2021 07:05 ET | Axsome Therapeutics, Inc.
Company to host conference call today at 8:00 AM Eastern NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies...
axsomelogo-468x57.jpg
Axsome Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
May 10, 2021 07:00 ET | Axsome Therapeutics, Inc.
Company to host conference call today at 8:00 AM Eastern NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies...
axsomelogo-468x57.jpg
Axsome Therapeutics to Report First Quarter 2021 Financial Results on May 10, 2021
April 27, 2021 07:00 ET | Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Monday, May 10, 2021 at 8:00 AM Eastern Time NEW YORK, April 27, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical...
axsomelogo-468x57.jpg
Axsome Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
March 01, 2021 07:00 ET | Axsome Therapeutics, Inc.
Company to host conference call today at 8:00 AM Eastern NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel...
axsomelogo-468x57.jpg
Axsome Therapeutics to Present at Upcoming Investor Conferences
February 19, 2021 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
axsomelogo-468x57.jpg
Axsome Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on March 1, 2021
February 16, 2021 07:00 ET | Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Monday, March 1, 2021 at 8:00 AM Eastern Time NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical...
axsomelogo-468x57.jpg
Axsome Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
November 05, 2020 07:00 ET | Axsome Therapeutics, Inc.
COMET Phase 3 long-term safety trial of AXS-05 in MDD, and MOVEMENT Phase 3 long-term safety trial of AXS-07 in migraine completed NDA submissions for AXS-05 in depression expected in January 2021,...
axsomelogo-468x57.jpg
Axsome Therapeutics Announces $225 Million Term Loan Facility with Hercules Capital
September 29, 2020 07:00 ET | Axsome Therapeutics, Inc.
Non-dilutive committed capital extends cash runway into at least 2024 Facility strengthens balance sheet through anticipated commercial launches of Axsome’s two lead CNS product candidates NEW YORK,...
axsomelogo-468x57.jpg
Axsome Therapeutics Announces Expedited Development of AXS-12 for the Treatment of Narcolepsy Based on FDA Breakthrough Therapy Meeting
September 21, 2020 07:00 ET | Axsome Therapeutics, Inc.
Single Phase 3 trial to be conducted to support an NDA filing of AXS-12 in the treatment of narcolepsy; trial initiation anticipated 1Q 2021 Extensive patient safety database, previously obtained...